Literature DB >> 9279563

Immunohistochemical assessment of proliferative activity in mammary adenomyoepithelioma.

M Koyama1, H Kurotaki, N Yagihashi, S Aizawa, M Sugai, Y Kamata, T Oyama, S Yagihashi.   

Abstract

AIMS: Two cases of adenomyoepithelioma of the breast were examined by immunohistochemistry to evaluate proliferative activity of epithelial and myoepithelial components. METHODS AND
RESULTS: The tumours showed a bicellular pattern of gland-forming epithelial cells and proliferative myoepithelial cells with clear cytoplasm. They showed foci of monotonous growth of myoepithelial cells devoid of glands with low mitotic rate (1-2/10 high-power fields) and mild cytological atypia. Immunohistochemically, the glandular cells were positive for epithelial membrane antigen, cytokeratin (KL-1 and CAM5.2) and carcinoembryonic antigen, whereas tumour cells with clear cytoplasm were reactive with muscle-specific actin (MSA), alpha smooth muscle actin, vimentin, and S100 protein but negative for desmin. Proliferative activities assessed by MIB-1 (Ki-67)/MSA positive cell index were greater in myoepithelial cells in both cases (19.2% and 17.7%) as compared to those in epithelial cells (MIB-1/CAM5.2 index: 10.2% and 9.5%).
CONCLUSIONS: These results might account for the previous findings that myoepithelial components predominate over the epithelial ones in an advanced stage of this tumour as well as in recurrent or metastatic lesions.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9279563     DOI: 10.1046/j.1365-2559.1997.2100842.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  2 in total

1.  Immunohistochemical demonstration of histone H1(0) in human breast carcinoma.

Authors:  Nora N Kostova; Ljuba N Srebreva; Angel D Milev; Olga G Bogdanova; Ingemar Rundquist; Herbert H Lindner; Dimiter V Markov
Journal:  Histochem Cell Biol       Date:  2005-11-03       Impact factor: 4.304

2.  Malignant Adenomyoepithelioma of the Breast and Responsiveness to Eribulin.

Authors:  Suee Lee; Sung Yong Oh; Sung-Hyun Kim; Ji Hyun Lee; Dae Cheul Kim; Se Heon Cho; Miri Lee; Hyo-Jin Kim
Journal:  J Breast Cancer       Date:  2015-12-23       Impact factor: 3.588

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.